US9809810B2 - Galvanotaxis assay for quantitative assessment of the metastatic potential of cancer cells - Google Patents

Galvanotaxis assay for quantitative assessment of the metastatic potential of cancer cells Download PDF

Info

Publication number
US9809810B2
US9809810B2 US14/765,993 US201414765993A US9809810B2 US 9809810 B2 US9809810 B2 US 9809810B2 US 201414765993 A US201414765993 A US 201414765993A US 9809810 B2 US9809810 B2 US 9809810B2
Authority
US
United States
Prior art keywords
electric field
electromagnetic coil
cancer cells
migration
induced electric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US14/765,993
Other versions
US20150376598A1 (en
Inventor
Vish Subramaniam
Joseph West
Emily Alkandry
Mohd Nasser
Dinesh Ahirwar
Ramesh Ganju
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ohio State Innovation Foundation
Original Assignee
Ohio State Innovation Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ohio State Innovation Foundation filed Critical Ohio State Innovation Foundation
Priority to US14/765,993 priority Critical patent/US9809810B2/en
Publication of US20150376598A1 publication Critical patent/US20150376598A1/en
Assigned to OHIO STATE INNOVATION FOUNDATION reassignment OHIO STATE INNOVATION FOUNDATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ALKANDRY, EMILY, WEST, JOSEPH, GANJU, RAMESH, SUBRAMANIAM, Vish, AHIRWAR, Dinesh, NASSER, Mohd
Application granted granted Critical
Publication of US9809810B2 publication Critical patent/US9809810B2/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N2/00—Magnetotherapy
    • A61N2/004—Magnetotherapy specially adapted for a specific therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N2/00—Magnetotherapy
    • A61N2/02—Magnetotherapy using magnetic fields produced by coils, including single turn loops or electromagnets
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M23/00—Constructional details, e.g. recesses, hinges
    • C12M23/02—Form or structure of the vessel
    • C12M23/12—Well or multiwell plates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M25/00—Means for supporting, enclosing or fixing the microorganisms, e.g. immunocoatings
    • C12M25/02—Membranes; Filters
    • C12M25/04—Membranes; Filters in combination with well or multiwell plates, i.e. culture inserts

Definitions

  • the present invention is directed to an apparatus and method of accelerating and/or inhibiting metastasis of cells by subjecting the cells to an electric field. More particularly, the present invention is directed to an apparatus and method for accelerating and/or inhibiting metastasis of cancer cells by applying a time-varying magnetic field to induce eddy currents that promote electrotaxis (galvanotaxis) of cells without the need for chemokines or glucose.
  • a time-varying magnetic field from an electromagnetic (EM) coil is used to induce electric fields in a modified version of Corning's Transwell permeable assay.
  • EM electromagnetic
  • the modified assay provides a novel method to study and quantify metastasis. For example, metastatic cell lines can be compared to each other in these assays by subjecting them to the EM fields and counting the number of cells that migrate across the permeable membrane. Comparisons between cell lines can also be drawn and quantified in the presence of both EM fields and chemokines.
  • Quantification can be accomplished by counting the cells or by digitizing the image and calculating cell coverage areas on the bottom of the membrane.
  • the EM coil is driven using a function generator using a 20 Vpp, 100 kHz, sawtooth wave with a sharp ⁇ 50 ns drop to generate a rapidly time-varying magnetic field.
  • the method is comprised of the steps of:
  • an electromagnetic coil having a first end and a second end
  • the waveform applied to the coil is a 20 volts peak to peak, 100 kHz sawtooth waveform with a 50 ns drop off at its trailing edge that induces a rapidly time-varying magnetic field.
  • the characteristics of the waveform can be adjusted to control metastasis.
  • FIG. 1 illustrates an assay with an insert with a porous membrane
  • FIGS. 2A-2C illustrate one embodiment of the apparatus of the present invention having an EM coil placed between two rows of wells
  • FIG. 3 illustrates microscopic images of the bottom of a permeable membrane showing migration of metastatic cancer cells across the membrane.
  • Corning's Transwell Permeable Support assay 10 An assay that is commonly used to evaluate the response of cancer cells to chemokines and chemotherapy drugs is Corning's Transwell Permeable Support assay 10 .
  • inserts 12 with porous membranes 16 at the bottom are placed into standard plate wells as shown in FIG. 1 .
  • a suitable chemokine placed in the lower compartment 18 With a suitable chemokine placed in the lower compartment 18 , a monolayer of cells can be made to migrate from the upper compartment 14 to the lower compartment.
  • the infiltration capabilities of cancer cells may be studied by observing the number that migrate from the membrane side in contact with the upper compartment to the membrane side in contact with the lower compartment.
  • chemotaxis refers to the motility of cells under the action of a gradient in the concentration of a chemical substance such as growth factors or chemokines.
  • Biological cells move in response to other forces as well, such as electrical forces.
  • the directional movement of biological cells in the presence of an applied electric field is known as Galvanotaxis or electrotaxis. This effect is named after Luigi Galvani, who in the 18 th century discovered bioelectricity.
  • the majority of experiments related to galvanotaxis over the past two centuries have involved steady electric fields applied via electrodes placed in contact with the medium containing cells (usually, the electrodes are in contact with the medium containing the cells through agar filled tubes and the applied electric field is usually DC).
  • the system and method of the present invention is used for inducing electric fields in the medium containing cells, for example the Corning's Transwell permeable assay, by applying time-varying magnetic fields.
  • the method uses electromagnetic (EM) induction to induce electric fields and eddy currents in the medium to promote galvanotaxis of cells without the need for chemokines or glucose. This is of significance since cancer cells are known to respond to externally applied electric fields so that they can be distinguished from normal cells. Moreover, metastatic potential of different cancer cells may be quantitatively evaluated by counting the number of cells migrated across the membrane, so that this can form the basis for a new assay.
  • EM electromagnetic
  • a SCP2 cell line cultured in Dulbecco's Modified Eagle Medium (DMEM) without serum with a density of 3.3 ⁇ 10 6 cells/mL is used.
  • This cell line is a highly metastatic estrogen receptor (negative) breast cancer cell line derived from the MDA-MB-231 cell line.
  • 150 ⁇ L of the medium containing this cell line ( ⁇ 4.95 ⁇ 10 4 cells) is pipetted into the upper compartment of a single Transwell permeable insert (equipped with a 6 ⁇ m filter) while the lower compartment has 200 ⁇ L of the same medium but with no cells.
  • EM horizontally oriented electromagnetic
  • FIGS. 2A-2C illustrate schematics of one embodiment of the apparatus 20 of the present invention with modified Corning Transwell plates 22 with the electromagnetic (EM) coil 24 placed in the middle of two rows 25 of wells. These components are placed in a holder 26 as shown.
  • the center line 28 of the coil is illustrated by the dashed line as shown.
  • the glass wells are preferably configured with offset holes to accommodate Corning Transwell permeable inserts with dimensions such that the centerline of the coil is at the same elevation as the membrane of the insert.
  • FIG. 2A illustrates a top view of the apparatus.
  • FIG. 2B illustrates a front view and
  • FIG. 2C illustrates a side view.
  • a single well with one insert is used, adjacent to the coil.
  • the entire apparatus is placed inside an incubator (at 37° C. with 5% CO 2 ) for a period of 12 hours.
  • an incubator at 37° C. with 5% CO 2
  • the EM coil is driven using a function generator using a 20 Vpp, 100 kHz, sawtooth wave with a sharp ⁇ 50 ns drop to generate a rapidly time-varying magnetic field with components B r and B z .
  • these temporally varying magnetic fields from the EM coil induce an electric field E ⁇ in the medium containing the cells due to the small but non-zero electrical conductivity of the medium. Because of the placement of the plate well relative to the coil, this results in a vertically directed electric field across the membrane, but with E ⁇ decaying radially with increasing distance from the coil.
  • E ⁇ switches directions back and forth (up and down) across the membrane, but with a non-equal component directed downward or upward depending on the side of the coil.
  • FIG. 3 illustrates microscopic images of a bottom of the permeable membrane showing differences between a control case 30 and a case where an EM field is applied 32 .
  • FIG. 3 shows coarse scale microscope images of a bottom of the permeable membrane in the control as well as in the insert subjected to the EM field.
  • application of the time-varying magnetic field results in induced electric fields which increase migration of the metastatic cancer cells across the membrane even in the absence of chemokines.
  • the control case (with no applied electric field) results in the typically observed random migration patterns.
  • the driving waveform e.g. waveform type, peak to peak voltage, and frequency
  • migration of cells can be reduced as shown in FIG. 2 by simply reversing the field. It should be noted that this result is of significance for cancer treatment where inhibition of metastasis in tumors may have beneficial effects in vivo.
  • Corning's Transwell assay can be modified to provide a method to quantify metastasis.
  • metastatic cell lines can be compared to each other in these assays by subjecting them to the same EM fields and counting the number of cells that migrate across the permeable membrane. The quantification can be accomplished by counting the cells or by digitizing the image and calculating cell coverage areas on the bottom of the membrane.
  • the effects of various drugs and chemokines may also be evaluated in the presence of EM fields so as to decipher the effects of in vivo endogenous electric fields that may adversely affect the therapeutic effects of chemotherapy drugs.
  • a time-varying magnetic field from an electromagnetic (EM) coil is used to induce electric fields in a modified version of Corning's Transwell permeable assay.
  • EM electromagnetic
  • Preliminary in vitro experiments on the highly metastatic SCP2 breast cancer cell lines show that cell migration across the membrane can be significantly increased compared to the control case where no EM field is applied.
  • chemokines suggests a natural means of quantifying the metastatic potential of different cancer cells as well as a natural means of comparing them with the motility of normal cells.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Sustainable Development (AREA)
  • Clinical Laboratory Science (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

An apparatus and method for accelerating and/or inhibiting the migration of cells by applying a time-varying magnetic field to induce eddy currents that promote electrotaxis (galvanotaxis) of cells without the need for chemokines or glucose. The present invention can also be used to study and quantify the metastatic potential of different cell lines.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS
This application claims priority to U.S. Provisional Application No. 61/760,987 filed on Feb. 5, 2013 and is herein incorporated by reference in its entirety.
BACKGROUND OF THE INVENTIVE FIELD
The present invention is directed to an apparatus and method of accelerating and/or inhibiting metastasis of cells by subjecting the cells to an electric field. More particularly, the present invention is directed to an apparatus and method for accelerating and/or inhibiting metastasis of cancer cells by applying a time-varying magnetic field to induce eddy currents that promote electrotaxis (galvanotaxis) of cells without the need for chemokines or glucose.
SUMMARY OF THE GENERAL INVENTIVE CONCEPT
In a preferred embodiment of the present invention, a time-varying magnetic field from an electromagnetic (EM) coil is used to induce electric fields in a modified version of Corning's Transwell permeable assay. By varying the characteristics of the excitation of the EM coil and the direction of application of the electric field, it is possible to accelerate cell migration as well as inhibit it, in the presence or absence of chemokines. The modified assay provides a novel method to study and quantify metastasis. For example, metastatic cell lines can be compared to each other in these assays by subjecting them to the EM fields and counting the number of cells that migrate across the permeable membrane. Comparisons between cell lines can also be drawn and quantified in the presence of both EM fields and chemokines. Quantification can be accomplished by counting the cells or by digitizing the image and calculating cell coverage areas on the bottom of the membrane. In one embodiment, the EM coil is driven using a function generator using a 20 Vpp, 100 kHz, sawtooth wave with a sharp ˜50 ns drop to generate a rapidly time-varying magnetic field.
In an exemplary embodiment of the present invention, the method is comprised of the steps of:
providing an electromagnetic coil having a first end and a second end;
connecting the electromagnetic coil to a function generator;
applying a time-varying sawtooth voltage waveform to the electromagnetic coil;
inducing a time-varying electric field around the electromagnetic coil;
placing the electromagnetic coil adjacent to the location of cancer cells with the direction of the induced electric field directed towards the cancer cells;
orientating the placement of the electromagnetic coil so that the direction of the electric field is directed away from an area of healthy cells; and
inhibiting migration of the cancer cells using the induced electric field.
In one embodiment the waveform applied to the coil is a 20 volts peak to peak, 100 kHz sawtooth waveform with a 50 ns drop off at its trailing edge that induces a rapidly time-varying magnetic field.
It is appreciated that the characteristics of the waveform can be adjusted to control metastasis.
Furthermore, the following additional steps may be taken according to one embodiment of the invention for studying and quantifying the metastatic potential of cell lines:
placing the electromagnetic coil in between a first row of a plurality of assay wells and second row of a plurality of assay wells;
providing a plurality of well inserts having a porous membrane;
placing one of the well inserts into each of the plurality of assay wells so that the wells are divided into a lower and upper compartment;
placing a medium into each of the plurality of assay wells;
placing a predetermined line of cancer cells into each of the assay wells;
allowing the predetermined lines of cancer cells to settle on top of the porous membranes;
taking an image of the porous membrane after the step of inducing a time-varying electric field;
quantifying metastatic potential of the predetermined lines of cancer cells; and
introducing a predetermined chemokine into each of the assay wells.
The foregoing and other features and advantages of the present invention will be apparent from the following more detailed description of the particular embodiments, as illustrated in the accompanying drawings.
BRIEF DESCRIPTION OF THE DRAWINGS
The following detailed description of the example embodiments refers to the accompanying figures that form a part thereof. The detailed description provides explanations by way of exemplary embodiments. It is to be understood that other embodiments may be used having mechanical and electrical changes that incorporate the scope of the present invention without departing from the spirit of the invention.
In addition to the features mentioned above, other aspects of the present invention will be readily apparent from the following descriptions of the drawings and exemplary embodiments, wherein like reference numerals across the several views refer to identical or equivalent features, and wherein:
FIG. 1 illustrates an assay with an insert with a porous membrane;
FIGS. 2A-2C illustrate one embodiment of the apparatus of the present invention having an EM coil placed between two rows of wells;
FIG. 3 illustrates microscopic images of the bottom of a permeable membrane showing migration of metastatic cancer cells across the membrane.
 DETAILED DESCRIPTION OF EXEMPLARY EMBODIMENT(S)
An assay that is commonly used to evaluate the response of cancer cells to chemokines and chemotherapy drugs is Corning's Transwell Permeable Support assay 10. In this assay, inserts 12 with porous membranes 16 at the bottom are placed into standard plate wells as shown in FIG. 1. With a suitable chemokine placed in the lower compartment 18, a monolayer of cells can be made to migrate from the upper compartment 14 to the lower compartment. In other words, by placing suitable chemokines in the lower compartment, the infiltration capabilities of cancer cells may be studied by observing the number that migrate from the membrane side in contact with the upper compartment to the membrane side in contact with the lower compartment. This is an example of chemotaxis, which refers to the motility of cells under the action of a gradient in the concentration of a chemical substance such as growth factors or chemokines. Biological cells move in response to other forces as well, such as electrical forces. The directional movement of biological cells in the presence of an applied electric field is known as Galvanotaxis or electrotaxis. This effect is named after Luigi Galvani, who in the 18th century discovered bioelectricity. The majority of experiments related to galvanotaxis over the past two centuries have involved steady electric fields applied via electrodes placed in contact with the medium containing cells (usually, the electrodes are in contact with the medium containing the cells through agar filled tubes and the applied electric field is usually DC).
The system and method of the present invention is used for inducing electric fields in the medium containing cells, for example the Corning's Transwell permeable assay, by applying time-varying magnetic fields. The method uses electromagnetic (EM) induction to induce electric fields and eddy currents in the medium to promote galvanotaxis of cells without the need for chemokines or glucose. This is of significance since cancer cells are known to respond to externally applied electric fields so that they can be distinguished from normal cells. Moreover, metastatic potential of different cancer cells may be quantitatively evaluated by counting the number of cells migrated across the membrane, so that this can form the basis for a new assay.
In one embodiment, a SCP2 cell line cultured in Dulbecco's Modified Eagle Medium (DMEM) without serum with a density of 3.3×106 cells/mL is used. This cell line is a highly metastatic estrogen receptor (negative) breast cancer cell line derived from the MDA-MB-231 cell line. In this embodiment, 150 μL of the medium containing this cell line (˜4.95×104 cells) is pipetted into the upper compartment of a single Transwell permeable insert (equipped with a 6 μm filter) while the lower compartment has 200 μL of the same medium but with no cells. The single plate well with the insert is then placed adjacent to a horizontally oriented electromagnetic (EM) coil (R˜22Ω, L=10 mH) and fixture as shown in FIG. 2.
FIGS. 2A-2C illustrate schematics of one embodiment of the apparatus 20 of the present invention with modified Corning Transwell plates 22 with the electromagnetic (EM) coil 24 placed in the middle of two rows 25 of wells. These components are placed in a holder 26 as shown. The center line 28 of the coil is illustrated by the dashed line as shown. The glass wells are preferably configured with offset holes to accommodate Corning Transwell permeable inserts with dimensions such that the centerline of the coil is at the same elevation as the membrane of the insert. FIG. 2A illustrates a top view of the apparatus. FIG. 2B illustrates a front view and FIG. 2C illustrates a side view. In another embodiment, a single well with one insert is used, adjacent to the coil. Once the cells are allowed to settle onto the upper surface of the permeable membrane (see FIG. 1), the entire apparatus is placed inside an incubator (at 37° C. with 5% CO2) for a period of 12 hours. As control case, a similar plate well with similar permeable insert and with the same highly metastatic cells, but not exposed to the EM coil, is also placed in the incubator. Both setups are imaged after a period of 12 hours.
In one embodiment, the EM coil is driven using a function generator using a 20 Vpp, 100 kHz, sawtooth wave with a sharp ˜50 ns drop to generate a rapidly time-varying magnetic field with components Br and Bz. By Faraday's law these temporally varying magnetic fields from the EM coil induce an electric field Eθ in the medium containing the cells due to the small but non-zero electrical conductivity of the medium. Because of the placement of the plate well relative to the coil, this results in a vertically directed electric field across the membrane, but with Eθ decaying radially with increasing distance from the coil. At the driving frequency of 100 kHz, Eθ switches directions back and forth (up and down) across the membrane, but with a non-equal component directed downward or upward depending on the side of the coil.
FIG. 3 illustrates microscopic images of a bottom of the permeable membrane showing differences between a control case 30 and a case where an EM field is applied 32. FIG. 3 shows coarse scale microscope images of a bottom of the permeable membrane in the control as well as in the insert subjected to the EM field. As illustrated by the figure, application of the time-varying magnetic field results in induced electric fields which increase migration of the metastatic cancer cells across the membrane even in the absence of chemokines. In contrast, the control case (with no applied electric field) results in the typically observed random migration patterns. By selecting a different set of characteristics for the driving waveform (e.g. waveform type, peak to peak voltage, and frequency) migration of cells can be reduced as shown in FIG. 2 by simply reversing the field. It should be noted that this result is of significance for cancer treatment where inhibition of metastasis in tumors may have beneficial effects in vivo.
In addition to implications for hindering metastasis, Corning's Transwell assay can be modified to provide a method to quantify metastasis. For instance, metastatic cell lines can be compared to each other in these assays by subjecting them to the same EM fields and counting the number of cells that migrate across the permeable membrane. The quantification can be accomplished by counting the cells or by digitizing the image and calculating cell coverage areas on the bottom of the membrane. The effects of various drugs and chemokines may also be evaluated in the presence of EM fields so as to decipher the effects of in vivo endogenous electric fields that may adversely affect the therapeutic effects of chemotherapy drugs.
In summary, a time-varying magnetic field from an electromagnetic (EM) coil is used to induce electric fields in a modified version of Corning's Transwell permeable assay. Preliminary in vitro experiments on the highly metastatic SCP2 breast cancer cell lines show that cell migration across the membrane can be significantly increased compared to the control case where no EM field is applied. By varying the characteristics of the excitation of the EM coil, it is possible to accelerate metastasis as well as inhibit it. This degree of control without the use of chemokines suggests a natural means of quantifying the metastatic potential of different cancer cells as well as a natural means of comparing them with the motility of normal cells.
While certain embodiments of the present invention are described in detail above, the scope of the invention is not to be considered limited by such disclosure, and modifications are possible without departing from the spirit of the invention as evidenced by the following claims:

Claims (10)

What is claimed is:
1. A method for controlling cell migration comprising the steps of:
providing an electromagnetic coil having a first end and a second end;
connecting the electromagnetic coil to a function generator;
applying a time-varying voltage waveform to the electromagnetic coil;
inducing a time-varying electric field around the electromagnetic coil;
placing the electromagnetic coil adjacent to, and without contacting, the location of cancer cells;
directing the induced electric field along an axis of migration of the cancer cells;
orientating the placement of the electromagnetic coil to control the direction of the induced electric field; and
reducing the migration of the cancer cells using the induced electric field.
2. A method according to claim 1 further comprising the step of:
inducing eddy currents near the location of the cancer cells.
3. A method according to claim 1, wherein the time-varying waveform is a sawtooth waveform.
4. A method according to claim 1, wherein the time-varying waveform is a 20 volts peak to peak, 100 kHz sawtooth waveform with a 50 ns drop off at its trailing edge.
5. A method according to claim 4, wherein the sawtooth waveform has a sharp drop and wherein the induced electric field is a rapidly time-varying magnetic field.
6. A method for controlling cell migration comprising the steps of:
providing an electromagnetic coil having a first end and a second end;
connecting the electromagnetic coil to a function generator;
applying a time-varying sawtooth voltage waveform to the electromagnetic coil;
inducing a time-varying electric field around the electromagnetic coil;
placing the electromagnetic coil adjacent to, and without contacting, the location of cancer cells;
directing the induced electric field along an axis of migration of the cancer cells, and wherein the induced electric field switches direction along the axis of migration with a non-equal component directed towards or away from a direction of migration;
orientating the placement of the electromagnetic coil to control the direction of the nonequal component of the induced electric field; and
reducing migration of the cancer cells using the induced electric field.
7. A method according to claim 6, wherein the time-varying waveform is a 20 volts peak to peak, 100 kHz sawtooth waveform with a 50 ns drop off at its trailing edge.
8. A method according to claim 6, wherein the sawtooth waveform has a sharp drop and wherein the induced electric field is a rapidly time-varying magnetic field.
9. A method according to claim 6, further comprising the steps of:
placing the electromagnetic coil in between a first row of a plurality of assay wells and second row of a plurality of assay wells;
providing a plurality of well inserts having a porous membrane;
placing one of the well inserts into each of the plurality of assay wells so that the wells are divided into a lower and upper compartment;
placing a medium into each of the plurality of assay wells;
placing a predetermined line of cancer cells into each of the assay wells; and
allowing the predetermined lines of cancer cells to settle on top of the porous membranes.
10. A method according to claim 1, wherein the induced electric field switches direction along the axis of migration with a non-equal component directed towards or away from a direction of migration; and further comprising the step of:
orientating the placement of the electromagnetic coil to control the direction of the nonequal component of the induced electric field.
US14/765,993 2013-02-05 2014-02-05 Galvanotaxis assay for quantitative assessment of the metastatic potential of cancer cells Active 2034-04-28 US9809810B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/765,993 US9809810B2 (en) 2013-02-05 2014-02-05 Galvanotaxis assay for quantitative assessment of the metastatic potential of cancer cells

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361760987P 2013-02-05 2013-02-05
PCT/US2014/014779 WO2014123947A1 (en) 2013-02-05 2014-02-05 A galvanotaxis assay for quantitative assessment of the metastatic potential of cancer cells
US14/765,993 US9809810B2 (en) 2013-02-05 2014-02-05 Galvanotaxis assay for quantitative assessment of the metastatic potential of cancer cells

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/014779 A-371-Of-International WO2014123947A1 (en) 2013-02-05 2014-02-05 A galvanotaxis assay for quantitative assessment of the metastatic potential of cancer cells

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US14/826,487 Continuation-In-Part US9885031B2 (en) 2013-02-05 2015-08-14 Galvanotaxis assay for quantitative assessment of the metastatic potential of cancer cells
US15/724,298 Division US10655121B2 (en) 2013-02-05 2017-10-04 Galvanotaxis assay for quantitative assessment of metastatic potential of cancer cells

Publications (2)

Publication Number Publication Date
US20150376598A1 US20150376598A1 (en) 2015-12-31
US9809810B2 true US9809810B2 (en) 2017-11-07

Family

ID=51300098

Family Applications (2)

Application Number Title Priority Date Filing Date
US14/765,993 Active 2034-04-28 US9809810B2 (en) 2013-02-05 2014-02-05 Galvanotaxis assay for quantitative assessment of the metastatic potential of cancer cells
US15/724,298 Active 2034-11-27 US10655121B2 (en) 2013-02-05 2017-10-04 Galvanotaxis assay for quantitative assessment of metastatic potential of cancer cells

Family Applications After (1)

Application Number Title Priority Date Filing Date
US15/724,298 Active 2034-11-27 US10655121B2 (en) 2013-02-05 2017-10-04 Galvanotaxis assay for quantitative assessment of metastatic potential of cancer cells

Country Status (2)

Country Link
US (2) US9809810B2 (en)
WO (1) WO2014123947A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10550383B2 (en) 2013-02-05 2020-02-04 Ohio State Innovation Foundation Galvanotaxis assay for quantitative assessment of the metastatic potential of cancer cells
US11027143B2 (en) 2020-02-06 2021-06-08 Vivek K. Sharma System and methods for treating cancer cells with alternating polarity magnetic fields
US11344740B2 (en) 2019-02-07 2022-05-31 Asha Medical, Inc. System and methods for treating cancer cells with alternating polarity magnetic fields
US11344739B2 (en) 2019-02-07 2022-05-31 Asha Medical, Inc. System and methods for treating cancer cells with alternating polarity magnetic fields
US12496455B1 (en) 2023-01-03 2025-12-16 Embiosys Inc. Wearable, non-invasive therapy device

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040152067A1 (en) 2002-07-20 2004-08-05 Xiaobo Wang Impedance based apparatuses and methods for analyzing cells and particles
US6790330B2 (en) 2000-06-14 2004-09-14 Board Of Regents, The University Of Texas System Systems and methods for cell subpopulation analysis
US7012100B1 (en) 2002-06-04 2006-03-14 Avolix Pharmaceuticals, Inc. Cell migration inhibiting compositions and methods and compositions for treating cancer
US7117034B2 (en) 2003-06-24 2006-10-03 Healthonics, Inc. Apparatus and method for bioelectric stimulation, healing acceleration, pain relief, or pathogen devitalization
US20060276858A1 (en) 2000-02-17 2006-12-07 Yoram Palti Apparatus and method for preventing the spread of cancerous metastases and for elimination of metastases
US20090018613A1 (en) 2006-08-02 2009-01-15 Genestim, Llc Regulation of vascular endothelial growth factor (vegf) gene expression in tissue via the application of electric and/or electromagnetic fields
US20100298624A1 (en) 2002-10-21 2010-11-25 Becker Paul F Method and apparatus for the treatment of physical and mental disorders with low frequency, low flux density magnetic fields
WO2011063458A1 (en) 2009-11-25 2011-06-03 University Of Sydney Membrane and membrane separation system
US20110194979A1 (en) 2007-03-12 2011-08-11 Fabrico Technology, Inc. Modulated magnetic permeability sensing assays
US8019414B2 (en) * 2006-04-05 2011-09-13 Novocure Ltd. Treating cancer using electromagnetic fields in combination with other treatment regimens
US20120035457A1 (en) 2009-02-13 2012-02-09 The Ohio State University Electromagnetic system and method

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7829334B2 (en) * 2006-09-21 2010-11-09 Tohoku University Cultured muscle cells with high metabolic activity and method for production of the cultured muscle cells
JP2012519483A (en) * 2009-03-03 2012-08-30 テヒニーセ・ユニベルシタイト・エイントホーヘン Apparatus and method for treating cells
JP2012527217A (en) * 2009-04-24 2012-11-08 ジ・オハイオ・ステート・ユニバーシティ Bidirectional microenvironment system
JP2013031408A (en) * 2011-08-03 2013-02-14 Sony Corp Cell culture device using electrically responsive functional material
CN105980541A (en) * 2014-01-22 2016-09-28 泽帕蒂卡股份有限公司 Method and apparatus for isolating invasive and metastatic cells for evaluating therapeutics and prediction of metastatic capacity
WO2017204111A1 (en) * 2016-05-26 2017-11-30 株式会社Ｉｆｇ Apparatus and method for non-contact electrical stimulation of cells in liquid culture medium

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060276858A1 (en) 2000-02-17 2006-12-07 Yoram Palti Apparatus and method for preventing the spread of cancerous metastases and for elimination of metastases
US6790330B2 (en) 2000-06-14 2004-09-14 Board Of Regents, The University Of Texas System Systems and methods for cell subpopulation analysis
US7012100B1 (en) 2002-06-04 2006-03-14 Avolix Pharmaceuticals, Inc. Cell migration inhibiting compositions and methods and compositions for treating cancer
US7700615B2 (en) 2002-06-04 2010-04-20 Avolix Pharmaceuticals, Inc. Cell migration inhibiting compositions and methods and compositions for treating cancer
US20040152067A1 (en) 2002-07-20 2004-08-05 Xiaobo Wang Impedance based apparatuses and methods for analyzing cells and particles
US20100298624A1 (en) 2002-10-21 2010-11-25 Becker Paul F Method and apparatus for the treatment of physical and mental disorders with low frequency, low flux density magnetic fields
US7117034B2 (en) 2003-06-24 2006-10-03 Healthonics, Inc. Apparatus and method for bioelectric stimulation, healing acceleration, pain relief, or pathogen devitalization
US8019414B2 (en) * 2006-04-05 2011-09-13 Novocure Ltd. Treating cancer using electromagnetic fields in combination with other treatment regimens
US20090018613A1 (en) 2006-08-02 2009-01-15 Genestim, Llc Regulation of vascular endothelial growth factor (vegf) gene expression in tissue via the application of electric and/or electromagnetic fields
US20110194979A1 (en) 2007-03-12 2011-08-11 Fabrico Technology, Inc. Modulated magnetic permeability sensing assays
US20120035457A1 (en) 2009-02-13 2012-02-09 The Ohio State University Electromagnetic system and method
WO2011063458A1 (en) 2009-11-25 2011-06-03 University Of Sydney Membrane and membrane separation system

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
Bullock, et al. The Effect of Induced Biphasic Pulsed Currents on Re-Epithelialization of a Novel Wound Healing Model, Bioelectromagnetics vol. 28 No. 1, Jan. 1, 2007, pp. 31-41.
Djamgoz, Mustafa B. A. et al., Directional Movement of Rat Prostate Cancer Cells in Direct-Current Electric Field: Involvement of Voltage-Gated Na+ Channel Activity, Journal of Cell Science 114 (14), 2001, pp. 2697-2705.
Fraser, Scott P. et al., Voltage-Gated Sodium Channel Expression and Potentiation of Human Breast Cancer Metastasis, Clinical Cancer Research 11, Aug. 1, 2005, pp. 5381-5389.
Hart, Francis X. et al., Keratinocyte Galvanotaxis in Combined DC and AC Electric Fields Supports an Electromechanical Transduction Sensing Mechanism, Bioelectromagnetics 34, Feb. 2013, pp. 85-94.
Song, et al. Application of Direct Current Electric Fields to Cells and Tissues in Vitro and Modulation of Wound Electric Field in Vivo. Nature Protocols. vol. 2 No. 6., Jun. 2007, pp. 1479-1489.
Sun, et al., Electrotaxis of lung cancer cells in ordered three-dimensional scaffolds, Biomicrofluids 6, 2012.
Vianale, et al. Extremely Low Frequency Electromagnetic Filed Enhances Human Keratinocyte Cell Growth and Decreases Proinflammatory Chemokine Productions. British Journal of Dermatology. vol. 158 No. 6., Jun. 2008, pp. 1189-1196.
Yan, Xiaolong. et al., Lung Cancer A549 Cells Migrate Directionally in DC Electric Fields with Polarized and Activated EGFRs, Bioelectromagnetics 30, 2009, pp. 29-35.

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10550383B2 (en) 2013-02-05 2020-02-04 Ohio State Innovation Foundation Galvanotaxis assay for quantitative assessment of the metastatic potential of cancer cells
US11344740B2 (en) 2019-02-07 2022-05-31 Asha Medical, Inc. System and methods for treating cancer cells with alternating polarity magnetic fields
US11344739B2 (en) 2019-02-07 2022-05-31 Asha Medical, Inc. System and methods for treating cancer cells with alternating polarity magnetic fields
US11577089B2 (en) 2019-02-07 2023-02-14 Asha Medical, Inc. System and methods for treating cancer cells with alternating polarity magnetic fields
US11583692B2 (en) 2019-02-07 2023-02-21 Asha Medical, Inc. System and methods for treating cancer cells with alternating polarity magnetic fields
US11931593B2 (en) 2019-02-07 2024-03-19 Asha Medical, Inc. System and methods for treating cancer cells with alternating polarity magnetic fields
US11944837B2 (en) 2019-02-07 2024-04-02 Asha Medical, Inc. System and methods for treating cancer cells with alternating polarity magnetic fields
US12415086B2 (en) 2019-02-07 2025-09-16 Asha Medical, Inc. System and methods for treating cancer cells with alternating polarity magnetic fields
US12539431B2 (en) 2019-02-07 2026-02-03 Asha Medical, Inc. System and methods for treating cancer cells with alternating polarity magnetic fields
US11027143B2 (en) 2020-02-06 2021-06-08 Vivek K. Sharma System and methods for treating cancer cells with alternating polarity magnetic fields
US12496455B1 (en) 2023-01-03 2025-12-16 Embiosys Inc. Wearable, non-invasive therapy device

Also Published As

Publication number Publication date
US20180037882A1 (en) 2018-02-08
US20150376598A1 (en) 2015-12-31
US10655121B2 (en) 2020-05-19
WO2014123947A1 (en) 2014-08-14

Similar Documents

Publication Publication Date Title
US10655121B2 (en) Galvanotaxis assay for quantitative assessment of metastatic potential of cancer cells
US20240325731A1 (en) Integrated circuits for neurotechnology and other applications
US10550383B2 (en) Galvanotaxis assay for quantitative assessment of the metastatic potential of cancer cells
Kang et al. Nanofountain probe electroporation (NFP-E) of single cells
Prinz Interactions between semiconductor nanowires and living cells
Čemažar et al. Enhanced contactless dielectrophoresis enrichment and isolation platform via cell-scale microstructures
US9140684B2 (en) Device to expose cells to fluid shear forces and associated systems and methods
CN103221091B (en) Molecular delivery with nanowires
US20020036142A1 (en) Systems and methods for cell subpopulation analysis
KR102156527B1 (en) Non-contact electrical stimulation device and non-contact electrical stimulation method of cells in culture medium
Chen et al. Isolating and concentrating rare cancerous cells in large sample volumes of blood by using dielectrophoresis and stepping electric fields
CN105683745A (en) Method and apparatus for isolation, capture and molecular analysis of target particles
CN101343613A (en) Flexible high-throughput cell electrofusion microelectrode array chip device
Ahirwar et al. Non-contact method for directing electrotaxis
JPWO2008018390A1 (en) Cell patterning method
Ino et al. Electrochemical device with interdigitated ring array electrodes for investigating the relationship between cardiomyocyte differentiation from embryonic stem cells and alkaline phosphatase activity
US9486626B2 (en) Passive electric field focus system for in vivo and in vitro applications
Koester et al. Recording electric potentials from single adherent cells with 3D microelectrode arrays after local electroporation
CN113588950A (en) Radio chemical visual analysis method for single-cell antigen
CN103966090A (en) Detachable electroporation pore plate device
JP2006333861A (en) Method for electrically stimulating cultured muscular cell by using transparent electrode
Tonomura et al. Parallel multipoint recording of aligned and cultured neurons on micro channel array toward cellular network analysis
Schor et al. Dielectrophoretic sorting of lipid-containing microorganisms using high frequency electric fields produced by conducting post arrays
KR20110095442A (en) Cell culture device incorporating physical stimulator capable of shock stimulation of magnetic particles
Chan et al. Exposure of MDA-MB-231 Cells to Dielectrophoretic Fields for Electroporation and Cancer Diagnostics

Legal Events

Date Code Title Description
AS Assignment

Owner name: OHIO STATE INNOVATION FOUNDATION, OHIO

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WEST, JOSEPH;ALKANDRY, EMILY;NASSER, MOHD;AND OTHERS;SIGNING DATES FROM 20170125 TO 20170501;REEL/FRAME:042882/0792

STCF Information on status: patent grant

Free format text: PATENTED CASE

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2551); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

Year of fee payment: 4

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2552); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

Year of fee payment: 8